As we transition to mid-stage development with our #ophthalmic pipeline and platform, and look to optimize the application of our technologies, Mark Gaffney’s decades of experience in corporate and financing strategy, business development and operations will be invaluable to Oxular’s future growth Oxular Announces Appointment of Mark Gaffney as Chief Executive Officer | Business Wire
David is the Interim Chief Executive Officer of Oxular and has more than 30 years of experience in various leadership roles within the ophthalmic pharmaceutical industry. He was previously Chief Executive Officer of Nightstar Therapeutics, a private biopharmaceutical company specialising in developing ocular gene therapies for patients with inherited retinal dystrophies, with David leading the …
Jim is the Chief Business Officer for Oxular. He is an accomplished and seasoned business development and strategy executive with over 20 years of creating value for pharma/biotech companies and their stakeholders. His prior work experience includes extensive experience as CBO at Rubius Therapeutics (a Flagship company focused on red blood cell therapies for oncology and auto-immune), Janssen, Alcon/Novartis and executive leadership roles at several boutique investment banks. Jim built and led the business development and M&A teams at Alcon for approximately 10 years where he was responsible for external growth strategies for its three global franchises in surgical, pharma, and consumer.
Tassos is an investment manager at IP Group and specializes in early stage investing in the life science sector. Before joining IP Group, Tassos was a business development executive at CRUK Commercial Partnerships (formerly CRT) where he led the intellectual property sourcing, licensing, and spin-out creation of CRUK-funded technologies. He has experience in technology transfer …
Oxular Limited Announces Acceptance of IND for Suprachoroidal OXU-001 for the Treatment of Diabetic Macular Edema OXU-001 represents potential best-in-class treatment for DME with just one, targeted administration per year Initiation of OXEYE Phase 2 clinical trial of OXU-001 in DME patients on-track for first quarter of 2023; Initial clinical data on safety and durability …
OXFORD, UK – November 7, 2022 – Oxular Limited, a clinical-stage retinal therapeutics company developing long-lasting targeted treatments for retinal disorders to improve patients’ vision, today announced the appointment of James “Jim” Jogerst as chief business officer, who will lead the company’s business development strategy, and oversee its current and planned strategic partnerships. Mr. Jogerst …
Marc is Oxular’s Senior Medical Advisor and a practicing vitreoretinal surgeon, with more than 30 years of experience in ophthalmic drug and medical device development. Previously, he was the National Eye Institute’s representative responsible for defining the clinical trial of Foscarnet, the first approved drug to treat CMV retinitis in AIDS patients. He initiated the …
Dina is a partner with NeoMed Management, and Advisor to Omega Funds. She has been investing in the private equity and venture capital healthcare industry in Europe and the US since 2001. Previously at 3i in London and Index Ventures in Geneva, Dina’s successful investments include Endosense, EUSA Pharma, Novexel, and Wilson Therapeutics. Dina serves …
David Fellows appointed as Chairman of Oxular’s Board of Directors David has more than 30 yearsof experience in various leadership roles within the ophthalmic pharmaceuticalindustry 10 January 2017 – Oxular Limited, the Oxford-based retinal therapeutics company, today announces the appointment of David Fellows, previously Non-Executive Director, as the Company’s Chairman of the Board. Mr. Fellows …
David Fellows appointed as Chairman of the Board Read More »
General
+44 (0)1865 636200
inquiries@oxular.com
Magdalen Centre
1 Robert Robinson Avenue
Oxford, OX4 4GA, UK
Limited company registered in
England and Wales
Registration No. 09331313
VAT No. GB 244 5883 81
Copyright Oxular Limited
Media
+1 617 895 9511
monique@thrustsc.com
Monique Allaire
Thrust
Follow us on
Limited company registered in England and Wales (Registration No. 09331313) VAT No. GB 244 5883 81
Copyright Oxular Limited
Website designed by Emerald Grove Studio
Website built by THRH Consulting